 |
|
Home | Barclays PLC (NYSE: BCS) Downgrades Arena Pharmaceuticals (NASDAQ: ARNA) |
 |
Barclays PLC (NYSE: BCS) Downgrades Arena Pharmaceuticals (NASDAQ: ARNA)
|
 |
- September 16, 2010
-
Barclays PLC (NYSE: BCS) equities research analysts downgraded shares of Arena Pharmaceuticals (NASDAQ: ARNA) from an equal-weight rating to an underweight rating in a research note to investors on Tuesday, with a price target of $3.00. Arena Pharmaceuticals, Inc. (Arena) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target [...]This article (Barclays PLC (NYSE: BCS) Downgrades Arena Pharmaceuticals (NASDAQ: ARNA)) was originally developed by and is property of American Banking News. Checkout American Banking News for up-to-date banking news and peer to peer lending news.
- Read more at:http://feedproxy.google.com/~r/AmericanBankingNews/~3/dvWf14-HhYU/
|
 |
|
 |
|
 |
